Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells

High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation

(2014) Doris M. Ponce et al.   BLOOD

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802

(2014) J. Bolanos-Meade et al.   BLOOD

Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients

(2013) Martino Introna et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients

(2013) Joanne Kurtzberg et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease

(2013) Lynne M. Ball et al.   BRITISH JOURNAL OF HAEMATOLOGY

Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study

(2013) Kazuo Muroi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death

(2013) Mark T. Vander Lugt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alterations in the Cellular Immune Compartment of Patients Treated with Third-Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell Transplantation

(2013) Regina Jitschin et al.   STEM CELLS

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

(2012) Paul J. Martin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Plasma biomarkers of lower gastrointestinal and liver acute GVHD

(2012) A. C. Harris et al.   BLOOD

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study

(2012) J. E. Levine et al.   BLOOD

Competing Risks and Multistate Models

(2012) C. Schmoor et al.   CLINICAL CANCER RESEARCH

Mesenchymal Stem/Stromal Cells Induce the Generation of Novel IL-10-Dependent Regulatory Dendritic Cells by SOCS3 Activation

(2012) X. Liu et al.   JOURNAL OF IMMUNOLOGY

Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring

(2012) E Dander et al.   LEUKEMIA

Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation

(2012) Giovanna Lucchini et al.   Stem Cells International

Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease

(2011) J. L. M. Ferrara et al.   BLOOD

Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial

(2011) J. A. Perez-Simon et al.   HAEMATOLOGICA

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

(2011) Richard Herrmann et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Primary Human mDC1, mDC2, and pDC Dendritic Cells Are Differentially Infected and Activated by Respiratory Syncytial Virus

(2011) Teresa R. Johnson et al.   PLoS One

Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells

(2011) S. Chiesa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population

(2010) Giovanna Lucchini et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host Disease in a Compassionate Use Study

(2010) Vinod K. Prasad et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The best endpoint for acute GVHD treatment trials

(2010) M. L. MacMillan et al.   BLOOD

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909

(2010) Jürgen Kuball et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like Profile

(2010) Julian Maggini et al.   PLoS One

Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin

(2010) S. Paczesny et al.   Science Translational Medicine

Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease

(2009) Partow Kebriaei et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

(2009) A. M. Alousi et al.   BLOOD

MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2

(2009) G. M. Spaggiari et al.   BLOOD

A biomarker panel for acute graft-versus-host disease

(2008) S. Paczesny et al.   BLOOD

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

(2008) M von Bonin et al.   BONE MARROW TRANSPLANTATION

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

(2008) Katarina Le Blanc et al.   LANCET